WHAT IS ISET
TAKE CONTROL OF YOUR FUTURE
The ISET® technology promises to improve the span and quality of life of patients with cancer. Such a highly sensitive technology will allow for a non-invasive, reliable and predictive diagnostic, which will bring remarkable help to people around the world in their struggle against cancer and save millions of lives through the early diagnosis of invasive cancers.
ISET® - Isolation by Size of Tumor cells
You never really see cancer coming, most of us learn we have a tumor during a routine check-up or when we are affected by the tumor. Once we have been diagnosed, our fight begins. Yes, cancer is a fight, and the ISET® technology may help you win this fight.
Cells are considered cancerous when they start growing without control in an organ and invade the surrounding tissue. As cancer cells invade the tissue around them, they can spread from the primary tumor into the blood. These cells are called Circulating Cancer Cells (CCC). With time the cancer cells can develop ways surviving by implanting and invading other parts of the body. These new tumors are called metastasis. Metastases are difficult to treat successfully and are the main reason why we lose our fight against cancer. Once the diffusion of Circulating Cancer Cells(CCC) has started, the race against time and disease begins.
ISET® Blood Cytopathology allows us to identify and count Circulating Cancer Cells. ISET® Blood Cytopathology may be used for early screening and follow-up. Patients can benefit from the early discovery of Circulating Cancer Cells which can be identified in blood years before metastases develop. This early diagnosis could allow an earlier start of a suitable therapy, considerably increasing the treatment's effectiveness. ISET® Blood Cytopathology may also determine the efficacy of the treatment and indicate whether or not additional or alternative treatment is indicated.
CANCER AND TUMOR INVASION
Circulating tumors cells are detectable before metastasis:
The very high sensitivity of ISET® allows its use for invasive cancers screening and as an alternative to biopsy.
Cytopathology can distinguish circulating non-tumor epithelial cells from circulating tumor cells; thus ISET can detect CTCs and CTM after surgery and invasive treatments when a high number of circulating non-tumor epithelial cells is released into the blood.
ISET enables the search for gene mutation in CTC and CTM as identified by the cytopathological analysis (ex: K-ras, HER2, etc..) for theranostics.
Circulating tumors cells are detectable before metastasis:
Distinction of CTC from Circulating epithelial non-tumor cells
Circulating tumor cells
Circulating epithelial non tumor cells
The ISET® technology is the fruit of 20 years of research of Prof. Patrizia Paterlini-Bréchot and her team at the University Paris Descartes and INSERM (Institut National de la Santé et de la Recherche Médicale). Patrizia Paterlini-Bréchot is a Professor of Cellular and Molecular Biology at the University Paris Descartes in Paris, France, and Hospital Practitioner at Assistance Publique-Hôpitaux de Paris. As an Oncologist and Hematologist, she and her team have studied cancer since 1982, and more specifically circulating tumor cells since 1995. The work of the team in fundamental and applied research led to the publication of high-level scientific studies in the field of predictive oncology. Oncology is the science devoted to the study and treatment of cancer. Predictive Oncology is the branch of Oncology, which predicts how and when a patient has to be treated to better fight against cancer.
In 2000, the work of Prof. Patrizia Paterlini-Bréchot’s team led to the invention of the ISET® technology: the first and still unparalleled filtration method for isolation of the very rare Circulating Tumor Cells (CTC) from blood, allowing their diagnostic identification by cytopathology and their molecular characterization. Once these cells are diagnostically validated by cytopathology after isolation by the ISET® technology, they are referred to as CCC, Circulating Cancer Cells.
LIMITATIONS OF THE BLOOD TEST
INFORMATION IF THE TEST IS PERFORMED ON PATIENTS WITHOUT DIAGNOSED CANCER*
The ISET® Blood Cytopathology test performed on patients without a diagnosed cancer can be done at any time, and even soon after an invasive act (ex. biopsy). It does not indicate, in a case of positive results of the test, the organ of origin of the CCC, and it cannot foretell the time lapse
before identification of the tumor by imaging is possible.
The positive result of the test carried out in the absence of a diagnosed cancer indicates the need for monitoring of the subject with the usual methods to be evaluated by your physician (imaging, blood tests, endoscopy..., etc.).
*The use of the ISET® Blood Cytopathology test for health monitoring and early detection of invasive cancer refers to the publication “Ilie M et Al, 2014**, a six years monocentric study. Other similar clinical research studies are ongoing, including multicenter validation studies. At this time, their result is not yet known. **Ilie M et al. : ‘Sentinel’’ Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease, PlosOne 2014
RESULTS OF THE BLOOD TEST
www.isetbyrarecells.com) and the study of more than 2000 patients. I the blood draw recommendations have been followed, a positive result (presence and number of CCC) indicates the tumor invasion of the blood compartment.
A negative result means that the patient's blood does not contain CCC at the time of the test. Possible difficulties of
Implementationandee www.rarecells.com The usual time to obtain the results is 20 working days (4 weeks) after the ISET® filter reaches the Cytopathology Centre. In exceptional cases, the period may be 20 business days. The sensitivity and specificity of the ISET® Blood Cytopathology test are close to 100%. The sensitive nature of CCC-isolation by the ISET® technology is one CCC in 10ml of blood. The ISET® technology has been validated by 50 high-level scientific publications (sand / or interpretation of the test will be reported. In this exceptional case, a new analysis will be performed at no charge.
ISET® BLOOD CYTOPATHOLOGY
ISET® Blood Cytopathology is based on a simple, painless for the patients', blood test. Once the blood is drawn, it is processed by a special device to isolate the CCC. The ISET® Technology is so sensitive that it can detect one single CCC in 10 mL of blood, (i.e., one CCC mixed with several billions of blood cells). CCC is spread by all types of solid tumors, and ISET® Blood Cytopathology can isolate all types of CCC. It combines the exceptional capability for isolating intact CCC from blood without loss, their staining, their diagnostic identification and their counting by cytopathology, with unequaled to date sensitivity and specificity. The ISET® analysis relies on cytopathology, which is the only diagnostic reference method in oncology to identify tumor cells. Cytopathology has been validated and used to diagnose cancer for over 150 years.